Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-100 vs BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.
Management of pain in opioid-tolerant patients requiring around-the-clock opioid analgesia for severe chronic pain,Anesthesia (adjunct to general or regional anesthesia),Procedural sedation,Patient-controlled analgesia (PCA),Breakthrough pain management (off-label use)
Relief of tension-type headache symptoms (FDA-approved),Treatment of migraine headache (off-label)
100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.
1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.
Terminal elimination half-life: 2–4 hours in adults; prolonged in elderly, hepatic impairment, or continuous infusion (due to redistribution).
Butalbital: 35-50 hours; Aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours at low doses, 15-30 hours at high doses; Caffeine: 3-7 hours; Codeine: 2.5-4 hours, morphine: 1.5-3.5 hours. Clinical context: Butalbital's long half-life contributes to prolonged sedation and risk of accumulation with repeated dosing.
Primarily hepatic via CYP3A4, with minor contribution from CYP3A5. Major metabolites: norfentanyl (inactive), despropionylfentanyl. Approximately 10-25% excreted unchanged in urine.
Butalbital: hepatic via CYP2C19 and other CYP enzymes, partly excreted unchanged; aspirin: hydrolyzed to salicylate, conjugated in liver; caffeine: hepatic via CYP1A2 (major), CYP2E1, and CYP3A4; codeine: hepatic via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and glucuronidation.
Primarily hepatic metabolism to inactive metabolites (norfentanyl, etc.); ~75% excreted in urine as metabolites, ~9% in feces, <10% unchanged in urine.
Codeine and its metabolites (morphine, codeine-6-glucuronide, norcodeine) are primarily excreted renally (>90%). Aspirin (acetylsalicylic acid) is hydrolyzed to salicylic acid, which is eliminated renally (75% as salicyluric acid, 10% as salicylic acid, 15% as other metabolites). Caffeine is largely metabolized in the liver and excreted renally (<3% unchanged). Butalbital is eliminated renally as metabolites and unchanged drug (about 60-70% as metabolites, 30-40% unchanged). Biliary/fecal elimination is minimal for all components.
~80–85% bound, primarily to albumin and alpha-1-acid glycoprotein.
Butalbital: 20-30% (albumin); Aspirin: dose-dependent, 50-80% to albumin; Caffeine: 25-35% (albumin); Codeine: 20-25% (albumin).
3–8 L/kg (large Vd indicates extensive tissue distribution, especially to fat and muscle).
Butalbital: 0.5-0.6 L/kg; Aspirin: 0.15-0.2 L/kg; Caffeine: 0.6-1.0 L/kg; Codeine: 3-6 L/kg. Clinical meaning: High Vd for codeine indicates extensive tissue distribution.
Oral: <40% (first-pass metabolism); Buccal: ~50%; Intranasal: 50–90%; Transdermal: ~30–60% (steady state).
Oral: Butalbital ~90%; Aspirin 80-100% (first-pass hydrolysis to salicylic acid); Caffeine ~100%; Codeine ~60-90% (first-pass metabolism to morphine).
GFR 30-50 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: reduce dose by 50-75% and extend dosing interval; GFR <10 m L/min: use with caution, consider alternative therapy; not removed by hemodialysis.
Cr Cl 10-50 m L/min: Administer at 75% of usual dose every 6 hours; Cr Cl <10 m L/min: Administer at 50% of usual dose every 6 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative; monitor for respiratory depression.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; Child-Pugh Class C: Contraindicated.
Intravenous: 0.5-2 mcg/kg/dose every 2-4 hours; transmucosal: 5-15 mcg/kg for procedural analgesia; transdermal patch: not recommended in children <2 years; in older children, use lowest effective dose based on body weight and opioid tolerance.
Not recommended for children under 12 years; for adolescents 12-18 years: 1 capsule orally every 4 hours as needed, not to exceed 4 capsules per day.
Start at 25-50% of adult dose; titrate slowly; avoid transdermal patch in opioid-naive elderly; monitor for delirium and respiratory depression; prefer intravenous or buccal routes with careful observation.
Initiate at lowest effective dose; consider reducing dose by 50% and extending interval to every 6 hours due to increased risk of respiratory depression, renal impairment, and aspirin-induced gastrointestinal bleeding.
Risk of respiratory depression, which may be fatal, especially in opioid-naive patients and when used in higher doses or with other CNS depressants. Risk of accidental exposure leading to fatal overdose. Risk of abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected paralytic ileus. Use only in opioid-tolerant patients for outpatient chronic pain management.
Risk of medication overuse headache; codeine: risk of addiction, abuse, misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks from concomitant use with benzodiazepines or other CNS depressants.
Respiratory depression: monitor closely, especially during initiation and dose titration. Abuse and addiction potential: fentanyl is a Schedule II controlled substance. Life-threatening respiratory depression with concurrent use of benzodiazepines or CNS depressants. Serotonin syndrome when coadministered with serotonergic drugs. Adrenal insufficiency. Severe hypotension, including orthostatic hypotension. Risk of seizures in patients with seizure disorders. Avoid use in patients with head injury or increased intracranial pressure. Biliary tract spasm. Use in pregnancy may cause neonatal opioid withdrawal syndrome. Avoid abrupt discontinuation to prevent withdrawal. Must be used only in opioid-tolerant patients for outpatient management.
Risk of Reye's syndrome with aspirin in children/viral illness; avoid exceeding recommended dosage due to rebound headache; GI bleeding risk with aspirin; opioid-induced respiratory depression, misuse, abuse, addiction; codeine use in children post-tonsillectomy/adenoidectomy; impaired alertness; risk of serotonin syndrome with serotonergic drugs; barbiturate dependence; caffeine withdrawal headache; hepatic/renal impairment; co-administration with alcohol or CNS depressants.
Hypersensitivity to fentanyl or any component of the product, significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, known or suspected gastrointestinal obstruction (including paralytic ileus), concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such therapy.
Hypersensitivity to any component; pediatric patients with chickenpox or influenza-like illness (aspirin); significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; breastfeeding (codeine); concurrent use with MAOIs or within 14 days; porphyria (barbiturates).
Avoid or limit alcohol and grapefruit juice as they can potentiate respiratory depression and alter fentanyl metabolism. Maintain adequate hydration and fiber intake to prevent constipation.
Avoid alcohol. High-fat meals may delay absorption. Avoid excessive caffeine intake from diet (coffee, tea, soda) to prevent additive stimulation. Maintain adequate hydration to reduce salicylate renal toxicity risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal opioid withdrawal syndrome; no structural malformations reported at therapeutic doses.
First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some studies. Second trimester: Risk of miscarriage with NSAIDs; codeine not clearly associated. Third trimester: Aspirin and codeine associated with premature closure of ductus arteriosus, oligohydramnios, neonatal hemorrhage, and respiratory depression; butalbital may cause neonatal withdrawal. Overall: Combination product has multiple teratogenic components; avoid in pregnancy unless benefit outweighs risk.
Fentanyl is excreted into breast milk in low concentrations; M/P ratio is approximately 0.4. Limited data suggest minimal risk at maternal doses; however, monitor infant for signs of sedation or respiratory depression. Avoid use with breastfeeding for 24 hours after administration due to long half-life.
Aspirin and caffeine are excreted in breast milk; codeine is excreted in low amounts but may cause CNS depression in infants, especially in CYP2D6 ultrarapid metabolizers. Butalbital is excreted in low amounts. M/P ratio: Not established for this combination; codeine M/P ratio approximately 0.2-0.4. Use with caution; monitor infant for sedation, respiratory depression, poor feeding.
No specific dose adjustment required for acute pain; however, increased clearance in late pregnancy may necessitate higher doses for chronic pain. Use lowest effective dose for shortest duration to minimize neonatal withdrawal risk.
Due to increased plasma volume and renal clearance in pregnancy, lower serum concentrations may occur. However, no specific dosing adjustments are recommended due to lack of data; use lowest effective dose for shortest duration. Avoid in third trimester if possible.
FENTANYL-100 transdermal patch is indicated only for opioid-tolerant patients with chronic pain requiring around-the-clock analgesia. Apply to non-irritated, non-hairy skin on upper torso or inner forearm; avoid heating pads, saunas, or sun exposure that increase absorption. Monitor for respiratory depression, especially in opioid-naive patients. Patches should be replaced every 72 hours; do not cut or damage the patch. Dispose of used patches by folding adhesive sides together and flushing down toilet.
Combination analgesic with opioid and non-opioid components. Hepatotoxicity risk from aspirin in children and adolescents (Reye syndrome). Measure serum salicylate and acetaminophen levels in overdose, but codeine is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy while ultra-rapid metabolizers risk toxicity. Avoid in patients with G6PD deficiency (aspirin-induced hemolysis). Caffeine may potentiate analgesia but also cause CNS stimulation and dependence. Prescribe with caution in elderly due to fall risk.
Apply the patch to clean, dry, hairless skin and press firmly for 30 seconds.,Do not expose the patch to direct heat sources (heating pads, hot tubs, electric blankets).,Keep away from children and pets; used patches must be flushed down toilet.,Do not drink alcohol or take other central nervous system depressants without consulting your doctor.,Report any difficulty breathing, extreme drowsiness, or confusion immediately.
This medication contains codeine, which can be habit-forming; use only as prescribed.,Do not take with other products containing acetaminophen, aspirin, or caffeine.,Avoid alcohol; may increase risk of liver damage and sedation.,Stop use and seek medical attention if you experience ringing in ears, severe nausea/vomiting, or signs of Reye syndrome (children).,Do not drive or operate machinery until you know how this drug affects you.,Keep out of reach of children; accidental overdose may be fatal.
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Agomelatine, a melatonergic antidepressant, combined with butalbital, a barbiturate and central nervous system (CNS) depressant, leads to additive CNS depression. This interaction increases the risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential overdose. Concurrent use may also alter hepatic metabolism via cytochrome P450 induction, reducing agomelatine efficacy and increasing butalbital toxicity."
"Amobarbital and Butalbital are both barbiturates that act as central nervous system (CNS) depressants. When co-administered, they exhibit additive CNS depression, leading to synergistic sedative and hypnotic effects, which can result in excessive sedation, respiratory depression, coma, or death. The combination significantly increases the risk of severe adverse outcomes, particularly in patients with compromised respiratory function or those taking other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-100 vs BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, answered by our medical review team.
FENTANYL-100 is a Opioid Agonist that works by Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-100 and BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-100 is: 100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.. The standard adult dose of BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is: 1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-100 and BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE. The risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-100 is classified as Category D/X. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal . BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is classified as Category D/X. First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some st. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.